Literature DB >> 9219825

Comparison of the site distribution of melanoma in New Zealand and Canada.

J L Bulliard1, B Cox, J M Elwood.   

Abstract

A comparison of the site distribution of cutaneous malignant melanoma in New Zealand and Canada was performed. This series deals with 41,331 incident cases registered between 1968 and 1990 and is the largest to date to evaluate the influence of age and gender on the site distribution of melanoma. Site-specific, age-standardized rates per unit surface area and relative tumour density were assessed by gender and country and differences compared with statistical techniques adapted to this context. The age-standardized rates for all sites were higher in New Zealand than in Canada, the ratio being 3.2 for men and 3.8 for women. Occurrence of melanoma was denser for chronically than intermittently exposed sites in both New Zealand and Canada. The highest incidence rate per unit area was for the ears in men which was more than 5 times the rate for the entire body in each country. For each gender, melanomas were relatively commoner on the trunk and the face in Canada, and on the lower limbs in New Zealand. The variations in the site distribution were similar in each country and consistent with the effect of differential patterns of sun exposure between genders. Our results show that the levels of risk of melanoma between phenotypically comparable populations exposed to different amount of UV radiation vary in a site-specific manner, especially for intermittently exposed sites. This suggests that both environmental conditions and lifestyle factors influence the site distribution of melanoma in these two populations.

Entities:  

Mesh:

Year:  1997        PMID: 9219825     DOI: 10.1002/(sici)1097-0215(19970717)72:2<231::aid-ijc5>3.0.co;2-s

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  8 in total

Review 1.  The melanomas: a synthesis of epidemiological, clinical, histopathological, genetic, and biological aspects, supporting distinct subtypes, causal pathways, and cells of origin.

Authors:  David C Whiteman; William J Pavan; Boris C Bastian
Journal:  Pigment Cell Melanoma Res       Date:  2011-08-16       Impact factor: 4.693

Review 2.  A new understanding in the epidemiology of melanoma.

Authors:  Esther Erdei; Salina M Torres
Journal:  Expert Rev Anticancer Ther       Date:  2010-11       Impact factor: 4.512

3.  Cutaneous melanoma: hints from occupational risks by anatomic site in Swedish men.

Authors:  B Perez-Gomez; M Pollán; P Gustavsson; N Plato; N Aragonés; G López-Abente
Journal:  Occup Environ Med       Date:  2004-02       Impact factor: 4.402

4.  Mechanism of UV-related carcinogenesis and its contribution to nevi/melanoma.

Authors:  Brozyna Anna; Zbytek Blazej; Granese Jacqueline; Carlson J Andrew; Ross Jeffrey; Slominski Andrzej
Journal:  Expert Rev Dermatol       Date:  2007

5.  Nevus density and melanoma risk in women: a pooled analysis to test the divergent pathway hypothesis.

Authors:  Catherine M Olsen; Michael S Zens; Therese A Stukel; Carlotta Sacerdote; Yu-Mei Chang; Bruce K Armstrong; Veronique Bataille; Marianne Berwick; J Mark Elwood; Elizabeth A Holly; Connie Kirkpatrick; Thomas Mack; Julia Newton Bishop; Anne Østerlind; Anthony J Swerdlow; Roberto Zanetti; Adèle C Green; Margaret R Karagas; David C Whiteman
Journal:  Int J Cancer       Date:  2009-02-15       Impact factor: 7.396

6.  The epidemiology of cutaneous malignant melanoma in Nova Scotia.

Authors:  Andrew L Howlett; Ron Ad Dewar; Steven F Morris
Journal:  Can J Plast Surg       Date:  2006

Review 7.  Personalized Medicine in Malignant Melanoma: Towards Patient Tailored Treatment.

Authors:  Hildur Helgadottir; Iara Rocha Trocoli Drakensjö; Ada Girnita
Journal:  Front Oncol       Date:  2018-06-12       Impact factor: 6.244

8.  Site-specific occurrence of nonmelanoma skin cancers in patients with cutaneous melanoma.

Authors:  R E Neale; D Forman; M F G Murphy; D C Whiteman
Journal:  Br J Cancer       Date:  2005-09-05       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.